Found: 5
Select item for more details and to access through your institution.
(QOL02) The Impact of Relapses on Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder: Data from the Phase 3 PREVENT Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 63
- By:
- Publication type:
- Article
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder.
- Published in:
- Frontiers in Neurology, 2023, v. 14, p. 1, doi. 10.3389/fneur.2023.1099376
- By:
- Publication type:
- Article
A Response to: Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder".
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 3, p. 1445, doi. 10.1007/s40120-022-00378-0
- By:
- Publication type:
- Article
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 1, p. 123, doi. 10.1007/s40120-021-00295-8
- By:
- Publication type:
- Article
Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
- Published in:
- Neurology & Therapy, 2021, v. 10, n. 2, p. 767, doi. 10.1007/s40120-021-00253-4
- By:
- Publication type:
- Article